Business
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower ...
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower natural killer (NK) cells to seek and destroy malignant cells. These next-generation approaches combine precision, potency, and the potential for fewer side effects than conventional treatments.","length":445,"tagName":"p"},{"type":"text","content":"The global oncology market is projected to nearly double from $139.4 billion in 2025 to $268.3 billion by 2034, expanding at a compound annual growth rate of 7.5%, according to Global Market Insights Inc. This growth reflects both rising cancer prevalence and increasing demand for innovative, targeted therapies.","length":313,"tagName":"p"},{"type":"text","content":"Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to harness NK cells against cancer. Its main candidate, GTB 3650, is currently being tested in Phase 1 trials for patients with relapsed or refractory acute myeloid leukemia, and the company is also working on treatments Early clinical progress and multiple upcoming milestones position GTBP as a notable player in the evolving immuno-oncology market.","length":446,"tagName":"p"},{"type":"text","content":"Advancing a Potent PlatformGTBP's TriKE platform focuses on NK cell engagers designed to activate and expand a patient's own immune cells. Second-generation TriKE molecules, built with camelid nanobody technology, are reported to be 10 to 40 times more potent than first-generation constructs. The lead program, GTB 3650, is undergoing a Phase 1 dose escalation study targeting CD33-positive hematologic malignancies, including AML and high-risk MDS. The FDA cleared t-positive2024, and enrollment began in January 2025.","length":529,"tagName":"p"},{"type":"text","content":"Clear Progress in Early CohortsThe trial includes up to seven cohorts, two patients each, with dose levels ranging from 1.25 µg/kg/day to 100 µg/kg/day. As of October 2025, all six patients in Cohorts 1 through 3 had been successfully treated. The Cohort 3 formal safety review revealed no tolerability issues. enabling progression to Cohort 4 at 10 µg/kg/day. Management described this dose as "more reflecti...